Testing is underway on vaccines to intercept brewing colon cancer before it takes root

Key Points:

• Dr. Stacy Norton, who has Lynch syndrome, participated in testing a new vaccine designed to prevent colorectal cancer by training the immune system to recognize and attack precancerous cells caused by the genetic mutation.
• Lynch syndrome, affecting about 1 million Americans, is caused by faulty mismatch-repair genes that greatly increase the risk of colorectal and other cancers, often requiring frequent colonoscopies to detect and remove precancerous polyps.
• Early clinical trials of vaccines targeting Lynch syndrome-related tumors, including those by Nouscom, Moderna, and ImmunityBio, have shown promising results in reducing precancerous growths and stimulating immune response.
• The rise in colorectal cancer cases among younger adults may be linked to undiagnosed Lynch syndrome, highlighting the importance of genetic testing and earlier screening for those with family histories or early-onset cancers.
• If successful, these vaccines could reduce the need for frequent invasive screenings and offer a proactive approach to cancer prevention for Lynch syndrome carriers and potentially others at high genetic risk.